After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)Zacks Investment Research • 03/20/25
After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)Zacks Investment Research • 03/19/25
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 03/13/25
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025GlobeNewsWire • 02/14/25
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GUGlobeNewsWire • 02/11/25
Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech ConferenceGlobeNewsWire • 01/28/25
Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid TumorsGlobeNewsWire • 12/09/24
FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical CancerGlobeNewsWire • 12/03/24
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity TherapiesSeeking Alpha • 11/11/24
Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation ConferenceGlobeNewsWire • 10/29/24
Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)GlobeNewsWire • 10/16/24
Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology SummitGlobeNewsWire • 09/26/24
Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' NowBenzinga • 09/23/24
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric EffectsInvestors Business Daily • 09/20/24
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts sayMarket Watch • 08/26/24
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a BetZacks Investment Research • 08/26/24
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston KungGlobeNewsWire • 08/20/24
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to TradeZacks Investment Research • 08/09/24
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 08/06/24
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in AugustGlobeNewsWire • 07/30/24